Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 10/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.44 |
| ▸ | GSK3B | P49841 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8948994 | 0.82 | ITGB3 (0.55) | HDAC3HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL8949190 | 0.80 | PHGDH (0.43) | HDAC3HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL7277324 | 0.78 | CASP1 (0.46) | — | |
| SCHEMBL13986939 | 0.73 | GSK3B (0.59) | HDAC3HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL8948996 | 0.72 | ITGB3 (0.43) | HDAC3HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL7275356 | 0.71 | KDM4E (0.51) | — | |
| SCHEMBL4857434 | 0.71 | GSK3B (0.59) | HDAC3HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL13986954 | 0.70 | GSK3B (0.55) | HDAC3HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL7286517 | 0.69 | TRPA1 (0.38) | GSK3B | |
| SCHEMBL15577629 | 0.69 | NOTUM (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611121-B1 | PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS | AVENTIS PHARMA SA (FR) | 2007-08-08 | — | — | EP | claimed |
| EP-1581505-B1 | PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-08-01 | — | — | EP | claimed |
| EP-1611121-B1 | PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS | AVENTIS PHARMA SA (FR) | 2007-08-08 | — | — | EP | disclosed |
| EP-1581505-B1 | PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-08-01 | — | — | EP | disclosed |
| US-5563268-A | FOR PREVENTING CELL AGGLOMERATION, TREATING THROMBOSIS, ARTERIOSCLEROSIS, BRAIN, LUNG OR CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-10-08 | — | — | US | disclosed |
| US-5418233-A | FOR INHIBITING CELL AGGREGATION | KARL THOMAE GMBH (DE) | 1995-05-23 | — | — | US | disclosed |
| EP-0537696-A1 | Heterobiaryl derivatives, medicines containing those compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-04-21 | — | — | EP | disclosed |